These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2979565)

  • 1. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
    Hanke J; Krajewska B
    Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder.
    Hein DW
    Bioessays; 1988 Dec; 9(6):200-4. PubMed ID: 3072000
    [No Abstract]   [Full Text] [Related]  

  • 3. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic regulation of N-acetyltransferase in target organs of arylamine tumors: homologous expression in human and hamster bladder and colon.
    Hein DW
    Proc West Pharmacol Soc; 1991; 34():55-60. PubMed ID: 1788341
    [No Abstract]   [Full Text] [Related]  

  • 5. [Significance of N-acetyltransferase phenotype in development of bladder neoplasms].
    Wolf H; Lower GM; Bryan GT
    Ugeskr Laeger; 1980 Feb; 142(6):382-5. PubMed ID: 7368384
    [No Abstract]   [Full Text] [Related]  

  • 6. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and its clinical implications: N-acetylation polymorphism.
    Horai Y; Ishizaki T
    Ration Drug Ther; 1987 Oct; 21(10):1-7. PubMed ID: 3326026
    [No Abstract]   [Full Text] [Related]  

  • 10. [The acetylator phenotype in patients with urinary bladder cancer].
    Wich H; Franke G; Grimm U; Siegmund W
    Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of genetic factors in bladder cancer.
    Schulte PA
    Cancer Detect Prev; 1988; 11(3-6):379-88. PubMed ID: 3390858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer.
    Weber WW; Hein DW; Litwin A; Lower GM
    Fed Proc; 1983 Nov; 42(14):3086-97. PubMed ID: 6628700
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
    Filiadis IF; Georgiou IA; Giannakopoulos X
    Br J Urol; 1998 Feb; 81(2):342-3. PubMed ID: 9488096
    [No Abstract]   [Full Text] [Related]  

  • 15. N-Acetyltransferase phenotype of patients with bladder cancer.
    Karakaya AE; Cok I; Sardas S; Gögüs O; Sardas OS
    Hum Toxicol; 1986 Sep; 5(5):333-5. PubMed ID: 3770769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indices of internal dose and metabolic polymorphism: an epidemiological biochemical study].
    Vineis P; Coda M; Caporaso N
    Epidemiol Prev; 1990 Jun; 12(43):63-4. PubMed ID: 2149111
    [No Abstract]   [Full Text] [Related]  

  • 19. N-acetyltransferase phenotype of patients with cancer of the larynx.
    Drózdz M; Gierek T; Jendryczko A; Pilch J; Piekarska J
    Neoplasma; 1987; 34(4):481-4. PubMed ID: 3658048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation phenotypes in patients with bladder carcinoma.
    Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
    Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.